Abstract: Hsp90 is a molecular chaperone playing a pivotal role in the cell life cycle. ATP-regulated internal dynamics are critical for its function and we recently demonstrated that they can be modulated in an allosteric fashion, targeting the protein C-terminal domain (CTD) with a family of 2-phenyl-benzofuran derivatives. Here we describe the expansion of the initial library, reporting 28 new derivatives that explore the chemical space at opposite ends of the benzofuran scaffold. Interaction of the compounds with the fulllength protein was explored by Saturation Transfer Difference (STD) NMR. In this context we report also the interaction epitope of Novobiocin, a known CTD inhibitor.
Introduction
Heat shock proteins (HSPs) are a group of chaperone proteins overexpressed by cells under stress conditions. Among them, Hsp90 has been shown to play a central role in the maturation of numerous client proteins involved in several cancer hallmarks. As such, Hsp90 represents a hub in a signaling network that controls cell cycle and apoptosis and it is established as a target in cancer therapy. This chaperone exists as a homodimer, each protomer consisting of four regions: an N-terminal ATP binding domain, a middle domain that completes the catalytic site, a charged region, and a C-terminal homodimerization domain. [1] A complex internal dynamics of the domains within the homodimer controls the chaperone activity of the protein and, with it, the downstream signalling pathways. This dynamic process is coupled to ATP hydrolysis and competitive inhibitors of ATP binding in Hsp90 N-terminal domain, such as geldanamycin or radicicol, [2] have shown potent antitumor activity in a wide-range of malignancies. [3] The amino-coumarin Novobiocin and its analogues [4] have been shown to bind the C-terminal domain (CTD) of Hsp90 and to lead to proteosomal degradation of the clients by inhibiting correct folding. Recently, small molecule activators of Hsp90 have been reported [5] and shown to act as allosteric modulators of ATPase activity. In particular, we have described a group of functionalized 2-(4-hydroxyphenyl)-3-methylbenzofurans (1, Figure 1 ) targeted against a computationally predicted allosteric site in Hsp90 and able to modify its enzymatic, conformational, co-chaperone and client-binding properties. [6] The best activators were shown to stimulate Hsp90 ATPase activity while simultaneously accelerating the rate of interprotomer closure dynamics, as revealed by FRET experiments. Some of these molecules were shown to affect the viability of cancer cell lines, including cells resistant to the geldanamycin derivative 17AAG, for which proper functioning of Hsp90 is required.
[5b] In the absence of X-ray structures, Molecular Dynamics (MD) simulations guided the ligand selection process and were also used to reveal the mechanisms of Hsp90 modulation by the allosteric ligands. [7] An ensemble approach was adopted to characterize chaperone-ligand interactions, with the aim of identifying the hot spots of the allosteric site where key functional groups on the ligand best complement the receptor, while taking the dynamic exchange between the binding partners explicitly into account. This process led to the definition of two regions on the ligand where functional group diversification could arguably translate into a modulated response of the chaperone: the 5-substituent of the benzofuran ring (R Here we describe the synthesis of 28 new derivatives in the active benzofuran series. These compounds were designed to expand the structure-activity relationship (SAR) observed in the initial generation for the R 1 and R 2 regions [7] and to explore the role played by specific structural features in determining compound potency. Hydrophilic and/or charged substituents were privileged, in an effort to increase the water solubility of the ligands. We also describe Saturation Transfer Difference (STD) NMR experiments with the yeast Hsp90 isoform, Hsc82, that confirm binding of the benzofuran ligands with the full protein. In this context, we present the first STD interaction study of Novobiocin with the same protein. STD data were combined to the MD-based characterization of the structures of Hsc82/allosteric ligand complexes.
[6b] The results indicate qualitative agreement between the two approaches, allowing to identify the ligand epitopes.
Results and Discussion
Diversification at R 1 The starting material for the group of benzofuran derivatives described so far is the 5-chloro-2-(4-hydroxyphenyl)-3-methylbenzofuran 1a that we synthesized from 2-bromo-4-chlorophenol by Pd-catalyzed enolate arylation, as previously described (Scheme 1). [8] O (iii) EtSNa, DMF 43% over the three steps (from [8] ).
The introduction of substituents other than chlorine at position 5 required a different approach, based on a [3, 3] -sigmatropic rearrangement of O-aryloximes described by Miyata et al [9] , in the one-pot version introduced by Contiero (Scheme 2). [10] Condensation of an aryloxyamine 2 with ketone 3 yields the intermediate O-aryloxime 4, which is heated at 60 °C in THF and with an excess of MeSO 3 H to induce sigmatropic rearrangement of the protonated enamine isomer. Re-aromatization of the intermediate, followed by intramolecular cyclization and ammonia elimination afford the desired benzofuran 1 in 3-6 h and satisfactory yields (Scheme 2). Conversion of the 4-trifluoromethyl derivative 4d required harsher conditions and was achieved in 45% yield by replacing THF with higher boiling dioxane and performing the reaction at 100 °C for 2 days. The starting aryloxyamines 2a-d were conveniently synthesized from N-hydroxyphthalimide 5 and the corresponding boronic acids 6a-d (Scheme 3) using a Cumediated cross-coupling procedure developed by Petrassi et al. [11] It has already been shown that 1a is a suitable substrate for Stille coupling reaction with tributyl(1-propenyl)tin. [8] The 5-bromo-2-(4-hydroxyphenyl)-3-methylbenzofuran 1b was instrumental to explore additional Pd catalyzed chemistry and to expand the library of 5-substituents. In particular, since calculations had suggested that the Hsp90 allosteric pocket may include complementary basic sites, a Heck [12] reaction was selected to introduce an acidic function to the benzofuran scaffold. Therefore, 1b and tBu acrylate were reacted in toluene affording the 5-substituted tBu ester 7 in 81% yields and 100% E selectivity (Scheme 4). Despite the acid sensitivity of the substrate, ester deprotection could be performed using 20% CF 3 COOH in CH 2 Cl 2 to afford acid 8 in quantitative yields. Double bond reduction was also successfully achieved on a set of derivatives and will be described below. 2 , P(o-tol) 3 , TEA, toluene, reflux, 6h, 81%; (ii) 20% CF 3 COOH in DCM, 2h, quant.
Diversification at R 2
Our initial set of data for R 2 substituents had shown that basic groups at this position improve the activity of the benzofuran ligands as stimulators of Hsp90. Thus, we focused our attention on the introduction of amino groups in this region. This was accomplished by phase transfer catalyzed (PTC) alkylation of the phenol oxygen of 1a, 1c and 7 with 2-chloro-N,Ndimethylethylamine 9 or 3-chloro-N,N-dimethylpropylamine 10 (Scheme 5) that allowed to obtain compounds 11-13 in good yields. The amino t-butylesters 14 and 18 (Scheme 5), obtained by alkylation of 7, were either directly deprotected (20% CF 3 COOH in CH 2 Cl 2 ) to give the corresponding N,Ndimethylamino acids 15 and 19, or hydrolyzed after reduction of the double bond (H 2 and 10% Pd-C) to afford 17 and 21.
In an effort to improve the solubility of the ligands, a second group of amine derivatives was prepared from epoxides 23 and 24, synthesized by alkylation of 1a and 1b with epichlorohydrin 22 (Scheme 6). Reaction of 23 with a set of four secondary amines in 9:1 CH 2 Cl 2 :EtOH mixture yielded compounds 25-28. Similarly, 32 was obtained by reaction of 24 with Nmethylpiperidine (Scheme 6). The primary amine 30 was prepared by NaN 3 opening of 23 (dioxane, 80°C, cat. Yb(OTf) 3 , 81% yield) and reduction of the resulting azide 29 under carefully controlled conditions (H 2 , PtO 2 , morpholine in MeOH, 71% yield), [13] to avoid hydrogenolysis of the arylchloride. Finally, HCl-promoted hydrolysis of 23 in 3:1 dioxane:water mixture afforded the diol 31 in 60% yields (Scheme 6). Two additional derivatives, 34 and 35 were prepared by activation of the known acid 33
[5b] and reaction with morpholine or N-methylpiperazine, respectively (Scheme 7). We have previously reported that a set of monoglycosides of 1a can modulate Hsp90 activity. In particular R 2 = -L-Rha, -DMan and -D-Gal were found to induce significant activation of Hsp90 ATPase.
[5b] In order to harness the effect of both a sugar and an amino group, the synthesis of glycoconjugates of amino sugars was also attempted (Scheme 8). Glycosylation of 1a with 6-azido-2,3,4-tri-O-benzoylmannose 1-trichloroacetimidate 36 [14] occurred in good yields (62%) under standard conditions (TMSOTf, -30°C) to afford the 6-azidomannoside 37 (Scheme 8). It is worth noting that, in the same conditions mannosylation of 1a with 2,3,4,6-tetra-O-benzoylmannose 1-trichloroacetimidate afforded only a modest 20% yield [8] . [15] under PTC conditions. Zemplén removal of the acetyl groups from 40 occurred under unusually harsh conditions (MeOH, 40 °C, 2 d), due to the low solubility of the starting material in MeOH, and yielded the 6-azidoglucoside 41 after precipitation from CH 2 Cl 2 . The compound was found to be soluble in acetone and could be fully characterized, but again we were unable to obtain clean reduction of the azido group. Glycosylation with other non-metabolic sugars was more successful. We focused on a limited group of commercially available monosaccharides, all characterized by the presence of an axial hydroxyl group either in position 2 or 4 of the pyranose ring, as suggested by the set of active glycosides identified in the previous campaign. The α-L-Man and the β-D-Fuc derivatives 42 and 43 (Table 1 ) are enantiomers of previously described derivatives [5b] and were synthesized accordingly. The L and D -arabinosides 44 and 45 were synthesized from the corresponding bromides, as exemplified in Scheme 9 for the L enantiomer. PTC alkylation of 1a with β-L-arabinopyranosyl bromide 2,3,4-triacetate 50 [16] followed by Zemplén hydrolysis of the acetyl groups afforded L-arabinoside 44 (60% overall yield) exclusively in the α configuration (note: for pentapyranosides, the anomeric substituent is () if in trans (cis) relative to the 4-hydroxy group [17] ). The anomeric configuration of the compound could be established based on the 1,2 coupling constant of 7 Hz, typical of a 1,2-trans glycoside. Under the same conditions, glycosylation of 1a with the α-L-lyxopyranosyl bromide 2,3,4-triacetate 51 [18] (Scheme 9) afforded the desired product in less than 10% yield. Thus the O-benzoxazole (O-Box) donor 53 was prepared from bromide 52 and used under Demchenko's conditions [19] to glycosylate 1a in overall 69% yields. Both anomers α-L-Lyx 54 and β-L-Lyx 55 were formed in this reaction in 56:44 ratio and were separated by flash chromatography (9:1 toluene/hexane). Their anomeric configuration and main conformation (shown in Scheme 9) were established by NMR experiments described in the Supporting Information. Benzoate removal afforded the final α-L-Lyx and β-L-Lyx glycosides 46 and 47. The D-enantiomers 48 and 49 were obtained by the same route, starting from the D-enantiomer of lyxose. 
Interaction of the compounds with Hsp90: STD-NMR experiments
While full characterization of the compounds activity on Hsp90 ATPase and functional dynamics is in progress, we set out to characterize the interaction of selected library members with Hsp90 using NMR spectroscopy. Saturation Transfer Difference (STD) NMR is one of the most widespread NMR methods to study the interaction between small molecules and macromolecular receptors.
[20] The technique exploits the nuclear Overhauser effect and relies on the fast exchange equilibrium for a ligand between the free and bound state, in the presence of the receptor. Selective irradiation of the protein is followed by transfer of magnetization to the ligand protons, which in turn causes a partial saturation of the ligand signals, allowing to map the interaction epitope on the small molecule by analyzing the difference spectrum obtained in the absence or in the presence of the selective irradiation pulse. The ligand protons that are in closer contact with the protein receive a larger amount of magnetization transfer and give larger signals in the difference spectrum. To the best of our knowledge, no STD experiments have been reported with full-length Hsp90. Thus, to test the feasibility of this experiment, we first analyzed Novobiocin 56 (Figure 2A ) in the presence of the yeast isoform of Hsp90, Hsc82. Novobiocin is the first and most studied inhibitor of the Hsp90 carboxy terminus. [21] To date, no co-crystal structure of Hsp90 bound to C-terminal ligands has been solved, so that information on the size and nature of the binding pocket and on ligands positioning is based exclusively on computational SAR and molecular docking studies.
[22] Novobiocin affinity for Hsp90 was estimated to be in the millimolar range by SPR and other techniques, [23] which makes it ideally suitable for STD analysis. However, NMR interaction experiments have never been reported, so far.
The STD spectrum of Novobiocin 56 in the presence of Hsc82 was obtained in deuterated phosphate buffer with a 200:1 ligand:protein ratio, using as irradiating frequency the upfield aliphatic region of the protein. The spectrum is reported in Figure 2C , together with the 1 H spectrum of Novobiocin 56 in the same conditions ( Figure 2B) . The molecule appears to be deeply embedded in the protein binding site since different degrees of magnetization transfer could be observed for each proton ( Figure 2C) . A quantitative analysis of these data ( Figure  2 and Supporting Information) suggests that the interaction epitope of Novobiocin strongly involves the prenylated phenol ring, the coumarin moiety and, to a lesser extent, the noviose ring. These observations are consistent with the results of MDbased studies of Hsc82/Novobiocin complexes.
[6b] In the latter, extensive MD simulation of 56 docked to the putative allosteric pocket were run and characterized by means of cluster analysis. The representative structure (Figures 3b, right panel) was largely consistent with STD, showing the prenyl, aromatic and sugar protons at contact distance with the protein. Additionally, the OCH 3 substituent at noviose 4' position was also calculated to point towards the interior of the protein, as consistent with the observed STD signal. NMR analysis of the benzofuran derivatives in the presence of Hsc82 was severely impaired by the low solubility of the compounds in water. Finally, conditions were established whereby compound 11 ( Figure 4A ) could be dissolved in the aqueous buffer at the appropriate concentration and maintained in solution after addition of the protein. The amine 11 has already been characterised as a powerful Hsp90 allosteric activator.
[5b] The predicted binding site ( Figure 3a ) is close to the region occupied by Novobiocin (Figure 3b ). However, MD simulations suggest that formation of the Hsp90:Novobiocin complex blocks the protein in a partially inactive state (Fig 3b, left panel), whereas interaction with 11 results in higher frequency turnover of the closed-active state (Fig. 3a , left panel) and allosterically stimulates ATPase activity. STD NMR experiments were recorded with a 200:1 ligand:protein ratio at different saturation times, using as irradiating frequency the upfield methyl region of the protein. A selected spectrum is reported in Figure 4C and the corresponding 1D spectrum is shown in Figure 4B . The results confirmed that binding occurs between compound 11 and Hsc82 and that the recognition is strongly mediated by aromatic protons (belonging both to the phenol and benzofuran rings). An intense STD signal was also observed for N-CH 2 and N-methyl groups. In particular, the protons of the aromatic rings show the largest saturation transfer and the N-CH 3 group the lowest effect, suggesting that the region of the ligand comprising the aromatic rings is making the closest contacts with the protein binding site. A competition experiment between 11 and Novobiocin was attempted, but it was frustrated by precipitation of the ligand. In good agreement with STD, the representative structures from MD simulations of the Hsc82/11 complex ( Figure  3a , right panel) show extensive packing of the benzofuran and aromatic rings of the ligand with the protein, coupled to contacts involving both the N-CH 2 and N-methyl groups of the amine modification. [7] Within the limitations of MD sampling for such large and complex systems, and with a caveat on the qualitative nature of the comparison, comparative analysis of STD and MD results provides a consistent structural model for the complexes in solution. It is worth noting, moreover, that such knowledge has been used to guide the development of more potent derivatives, providing further support to the validity of the model. 
Conclusions
A library of Hsp90 stimulators characterized by a 2-(4-hydroxyphenyl)-3-methylbenzofuran structure has been significantly expanded. Groups at position 5 of the benzofuran ring were diversified using a [3, 3] -sigmatropic rearrangement of O-aryloximes for the synthesis of the benzofuran core and a Heck cross-coupling reaction for further modifications. The synthesis of a second set of compounds, diversified at position R 2 was achieved by alkylation of the phenol ring followed by further elaborations. Glycosylation of 1a with amino sugars was attempted but abandoned due to low solubility of the products, while other non-metabolic sugars could be successfully introduced. Overall, 28 new compounds were synthesized, demonstrating the versatility of the benzofuran platform. STD-NMR analysis of the interaction of the known allosteric modulator 11 with the yeast isoform of Hsp90 (Hsc82) proved that the ligand actually binds to the protein and confirmed the role of the benzofuran scaffold in establishing the interaction. The spectra showed that also the substituents of the amino group are in close contact with the protein, providing a viable structural model that can be used to guide the development of more potent derivatives. Full characterization of the 28 new compounds activity on Hsp90 ATPase and functional dynamics is underway.
Experimental Section
Protein expression and purification: The Hsc82 cloned into pET28b (Novagen, U.S.) and transformed into BL21 (DE3) cells (NEB, U.S.). The protein expression was induced by 0.5 mM IPTG (Goldbio, U.S.) at 20 °C for 16 hours. The cells were lysed using EmulsiFlex-C3 (Avestin, Canada). The lysate was purified using Ni-NTA column (Qiagen, U.S.), monoQ ion exchange chromatography (GE, U.S.) and Superdex200 gel filtration chromatography (GE. U.S.).
STD-NMR:
All NMR spectra were recorded on a Bruker Avance spectrometer operating at 600 MHz. All data were collected at 298 K. 1D, COSY, and NOESY (mixing time of 200 and 700 ms) were recorded using standard sequences from Bruker library, on Novobiocin 56 (0.23 mg, MW=634.6, 2 mM) and Compound 11 (0.3 mg, MW=366.3, 4.5 mM) in order to assign all the resonances. The sample was prepared in deuterated 20 mM PBS buffer. Data were analysed using Bruker Topspin software. After NMR characterization, 30 µL of the Hsc82 solution (10 mg/mL, MW=80899.7) was added to each sample, giving to a 200:1 L/P ratio. For the acquisition of NMR Saturation Transfer Difference (STD) experiments, a 1D-pulse sequence incorporating a T 1ρ filter to remove disturbing protein signals was used. The STD spectra were performed with an on-resonance irradiation frequence at −0.05 ppm, while 200 ppm was chosen as off-resonance frequence. Selective presaturation of the protein was achieved by a train of Gauss shaped pulses, each of 49 ms in length. STD experiments were acquired on each sample varying the total saturation times from 0.49 to 3.92 s (with 0,49s increments). In STD experiments, water suppression was achieved by using the WATERGATE 3-9-19 pulse sequence. For both product blank experiments in absence of protein were performed.
Synthesis -general:
Dry dichloromethane (DCM), methanol, 1,4-dioxane and triethylamine (TEA) were distilled over calcium hydride; tetrahydrofuran (THF) was distilled over sodium. Dichloroethane (DCE) was dried over 4 Å molecular sieves and hexane (Hex) and toluene were used as purchased. Reactions requiring anhydrous conditions were performed under nitrogen, or argon where indicated. AgOBox was synthesized as reported. [ C (HMBC) experiments using standard pulse programs. Processing of the spectra was performed using TopSpin or MestReNova software. Sugar signals were numbered as customary; benzofuran signals were numbered as customary and indicated with the suffix Bf, and the substituents of benzofuran do not have any numbering, but they are clearly indicated in the characterizations; OBox signals were numbered as customary and indicated with the suffix Box. In the names of the compounds the conventional numbering is used. Mass spectra were obtained with a ThermoFisher LCQ apparatus (ESI ionization), or iontrap ESI Esquire 6000 from Bruker, or Apex II ICR FTMS (ESI ionization-HR-MS). Thin layer chromatography (TLC) was carried out with precoated Merck F254 silica gel plates. Flash chromatography (FC) was carried out with Macherey-Nagel silica gel 60 (230-400 mesh), according to Still's procedure. [24] Automated chromatography was performed using a BiotageIsolera Prime. Compounds 1a, 11, 12, 33, [5b] 1b, [9] 39 [15] and 50 [16] have been described previously. Glycosides 42 and 43 were characterized based on the spectral data reported for their enantiomers [8] and on the sign of their optical rotation. Boronic acids 57a-d and ketone 3 are commercially available. hydroxyphenyl)-3-methyl-benzofurans (1a-c) : [10] The phenyloxyamine hydrochloride 2a-c (1 mmol) was suspended in THF (3 mL) under nitrogen. Freshly activated, acid washed 4 Å molecular sieves (0.1 g) and 1-(4-hydroxyphenyl)propan-1-one 3 (1 mmol) were added. The solution was stirred for 5 min at 60 °C, then methanesulfonic acid (2 mmol) was added. The mixture was stirred for 5 h and the progress was followed by HP-TLC (8:2 Toluene:DCM, each sample was diluted with DCM and quenched with NaHCO 3 before deposition on TLC).The reaction mixture was then diluted with EtOAc, the organic phase was washed with NaHCO 3 (2x5 mL), and brine (2x5 mL), dried over anhydrous Na 2 SO 4 and concentrated in vacuo. The crude was purified by chromatography as described below.
General procedure I. Synthesis of the 5-substituted-2-(4-

5-chloro-2-(4-hydroxyphenyl)-3-methylbenzofuran (1a):
General procedure I performed starting from 2a. The crude was purified by flash chromatography (Toluene:DCM gradient from 10% to 25% DCM) leading in 51% yield to product 1a, whose spectral data corresponded with those reported in the literature [8] . 
5-bromo-2-(4-hydroxyphenyl)-3-methylbenzofuran (1b):
General procedure I performed starting from 2b. The crude was purified using an automated chromatography system (SiO 2 , Hex:EtOAc gradient from 30% to 100% EtOAc), to afford compound 1b in 70% yield as a white solid, whose spectral data corresponded with those reported in the literature. 
5-trifluoromethyl-2-(4-hydroxyphenyl)-3-methylbenzofuran (1d):
Phenyloxyamine hydrochloride 2d (1 mmol) was suspended in dioxane (3 mL) under nitrogen. Freshly activated, acid-washed 4 Å molecular sieves (0.1 g) and 1-(4-hydroxyphenyl)propan-1-one 3 (1 mmol) were added. The solution was stirred for 5 min at 40 °C, then methanesulfonic acid (2 mmol) was added and the mixture was stirred for 2 days at 100 °C. The reaction progress was followed by RP-HPLC (C18, H 2 O:CH 3 CN gradient from 30% to 100% CH 3 CN; retention time of 1d 1.36 min; retention time of the oxime intermediate 4d 1.38 min; each sample was diluted with DCM and quenched with NaHCO 3 before injection). The reaction mixture was diluted with EtOAc, the organic phase was washed with NaHCO 3 (2x5 mL), and brine (2x5 mL), dried over anhydrous Na 2 SO 4 and concentrated in vacuo. The crude was purified by flash chromatography (8:2 Hex:EtOAc, R f =0.4) leading to product 1c in 45% yield. 
E-t-butyl 3-(2-(4-hydroxyphenyl)-3-methylbenzofuran-5-yl)acrylate (7)
: [12] Compound 1b (131 mg, 0.43 mmol), Pd(OAc) 2 (1 mg, 0.043 mmol) and (o-tol) 3 P (5 mg, 0.017 mmol) were dissolved in toluene (800 μL) under nitrogen atmosphere. TEA (300 μL, 0.73 mmol) and tBuacrylate (76 μL, 0.52 mmol) were added. The mixture was warmed to reflux for 6 h (TLC 8:2 Hex:EtOAc). The reaction was cooled to room temperature and diluted with EtOAc. The mixture was washed with 1 M HCl (2x5 mL), water (2x5 mL) and brine (1x5 mL), dried over anhydrous Na 2 SO 4 and concentrated in vacuo. The crude was purified using an automated chromatography system (SiO 2 , Hex:EtOAc gradient from 30% to 100% EtOAc) to afford compound 7 (122 mg, 81% yield, 100% E selectivity) as a white solid. MeOH) it was diluted with chloroform and brine, the aqueous phase was extracted with chloroform (2x10 mL) and the organic phases were washed with water (2x20 mL), dried over Na 2 SO 4 and concentrated in vacuo.
5-fluoro-2-(4-(2-(dimethylamino)ethoxy)phenyl)-3-methylbenzofuran (13):
Prepared from 1c and 9, following the general procedure II. The crude was purified by flash chromatography (CHCl 3 + 1%TEA, R f =0.26) leading to product 13 in 81% yield. 
E-t-butyl-3-(2-(4-(2-(dimethylamino)ethoxy)phenyl)-3-methylbenzofuran-5-yl)acrylate (14):
Prepared from 7 and 9, following the general procedure II for phenol alkylation. The crude was purified using an automated chromatography system (SiO 2 , CHCl 3 :MeOH:TEA (1%) gradient from 0 to 20% MeOH) to afford the product as a white foam (50% yield). 
E-t-butyl-3-(2-(4-(3-(dimethylamino)propoxy)phenyl)-3-
5-chloro-3-methyl-2-(4-(oxiran-2-ylmethoxy)phenyl)benzofuran (23):
Obtained in quantitative yield by reaction of 1a and epichlorohydrin 22, following the general procedure II for phenol alkylation. TLC: 6:4 Hex:DCM, Rf=0.3. No purification required. 
5-bromo-3-methyl-2-(4-(oxiran-2-ylmethoxy)phenyl)benzofuran (24):
Prepared by reaction of 1b and epichlorohydrin 22, following the general procedure II for phenol alkylation. TLC: 6:4 Hex:DCM, R f =0.4.The crude was purified by flash chromatography (85:15 toluene:DCM, R f =0.3) and the product was isolated in 75% yield. 8 mL) of the t-butyl ester (7, 14, 16, 18 or 20; 0.1 mmol) under a flux of nitrogen, TFA (400 μL) was added dropwise. The reaction was stirred for 2 h then concentrated in vacuo. TFA was co-evaporated with toluene to afford pure product (quantitative yield) without any further purification. 
E-3-(2-(4-hydroxyphenyl)-3-methylbenzofuran-5-yl)acrylic acid (8):
E-3-(2-(4-(3-(dimethylamino)propoxy)phenyl)-3-methylbenzofuran-5-yl)acrylic acid (19):
Isolated as the trifluoroacetate salt after t-Bu ester removal from 18. 40 (d, 1 H, H-4Bf), 7.35 (d, 1 H, H-7Bf 
1-(4-(5-chloro-3-methylbenzofuran-2-yl)phenoxy)-3-(cyclopropylamino) propan-2-ol (27):
The epoxide 23 (20 mg, 63 µmol) was suspended in a solution of DCM/EtOH (0.6 mL, 9:1 ratio). Cyclopropylamine (13 µL, 0.19 mmol) was added to the reaction mixture. The reaction was stirred for 24 h at 40 °C. The reaction was followed by TLC chromatography (9:1:0. Oxalyl chloride (0.27 mmol, 2.0 M solution in dry DCM) was added to a solution of 33 (28.8 mg, 0.091 mmol) in dry DCM (0.9 mL) and the reaction was stirred at reflux under nitrogen atmosphere for 2 h. The solvent was co-evaporated with toluene at reduced pressure, the crude was re-dissolved in dry DCM (0.1 mL) and 1-methylpiperazine (300 µL, 2.7 mmol) was added. The reaction was stirred at 40 °C overnight (TLC 9:1:0.1 CHCl 3 :MeOH:TEA). The solvent was evaporated in vacuo and the crude was purified using an automatic system (SiO 2 , DCM:MeOH gradient from 0 to 14% MeOH) obtaining the desired product 35 (28 mg) as a white solid in 78% yield. [14] (0.17 g, 0.25 mmol) and phenol 1a (58 mg, 0.23 mmol) were co-evaporated three times with toluene and dissolved in dry DCM (4.6 mL) under nitrogen atmosphere. To the solution freshly activated 4 Å molecular sieves were added. The reaction mixture was cooled at -30 °C and TMSOTf (8.3 µL, 46 µmol) was slowly added. The reaction was stirred for 30 min and followed by TLC (9:1 toluene:EtOAc, R f =0.91). To the solution TEA (0.13 mL) was added. The reaction was warmed to room temperature and concentrated in vacuum. The crude was purified by flash chromatography (8:1:1 Hex:EtOAc:toluene) leading to product 37 (87 mg, 0.13 mmol) in 50% yield. [15] (189 mg, 0.48 mmol) and benzofuran 1a (40 mg, 0.16 mmol) were diluted in CHCl 3 (1.6 mL). To the reaction
